Gibbs Wealth Management Halozyme Therapeutics, Inc. Transaction History
Gibbs Wealth Management
- $442 Billion
- Q3 2025
A detailed history of Gibbs Wealth Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Gibbs Wealth Management holds 3,108 shares of HALO stock, worth $217,653. This represents 0.05% of its overall portfolio holdings.
Number of Shares
3,108
Previous 4,264
27.11%
Holding current value
$217,653
Previous $222 Million
2.75%
% of portfolio
0.05%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
666Shares Held
128MCall Options Held
626KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...